We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Effect of Amlodipine and Lisinopril on Retinal Autoregulation in Type 1 Diabetes

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: June 15, 2006
Last Update Posted: June 23, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Velux Fonden
Information provided by:
University of Aarhus
The purpose of this study is to compare the effect of two antihypertensive drugs on retinal vessel diameter in young type 1 diabetics. The retinal vessel analyzer (RVA) was used to investigate how the drugs affected vessel diameter, when the subjects were exposed to an increase in blood pressure, induced by isometric muscle contraction and when they were stimulated by flickering light.

Condition Intervention
Type 1 Diabetes Diabetic Retinopathy Eye Diseases Diabetes Complications Drug: Amlodipine Drug: Lisinopril

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Official Title: Lack of Effect of Antihypertensive Treatment With Amlodipine and Lisinopril on Retinal Autoregulation in Patients With Type 1 Diabetes and Mild Diabetic Retinopathy. A Prospective Randomized Clinical Trial.

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • Vessel diameter changes in arbitrary units as measured with the Retinal Vessel Analyzer [ Time Frame: 120,240,360,480,600,720 and at 840secs ]

Secondary Outcome Measures:
  • Blood pressure (mmHG) [ Time Frame: 120,240,360,600,720,840 secs ]
  • 24 hour ambulatory blood pressure (mmHg) [ Time Frame: 24 hours ]

Enrollment: 25
Study Start Date: July 2006
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Crossover design. Arm is same all the way
Drug: Amlodipine
1 (5mg) tablet daily, given 14 days totally before measure of outcome.
Drug: Lisinopril
Lisinopril 10 mg given daily for 14 days and then outcome was measured.

Detailed Description:

Diabetes is a leading cause of blindness in the western part of the world. Diabetic patients develop diabetic retinopathy which can progress to blindness. Diabetic retinopathy is associated with an increase of blood flow in the retinal vessels, ischaemia in the periphery and macular oedema. It has been shown in previous trials, that the pressure and metabolic autoregulation is disturbed in patients with diabetes, and it is believed to contribute to the development of diabetic retinopathy.

In healthy subjects the retinal arterioles will contract during an increase in blood pressure, but trials have shown that this response is impaired in diabetics. When the retina is exposed to flickering lights, the metabolism increase and the arterioles in healthy subjects dilates. In diabetics this dilation is impaired. In this trial we want to investigate if an ACE-inhibitor (lisinopril) or calcium channel blocker (amlodipine) influence this response in subjects exposed to increased blood pressure vs increased retinal metabolism.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 35 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 1 diabetes
  • 18-35 years of age
  • Simplex retinopathy at last screening (Less than 10 retinal haemorrhages at the nearest ordinary screening examination)
  • normotensive (BP not above 160 mmHg systolic or 100 mmHg diastolic)

Exclusion Criteria:

  • Pregnancy
  • Systolic Bloodpressure above 160 mmHg
  • Diastolic bloodpressure above 100 mmHg
  • Retinopathy grade higher than simplex retinopathy
  • Prior retinal laser photocoagulation
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00337298

Aarhus university hospital
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Velux Fonden
Principal Investigator: Toke Bek, MD, PhD Aarhus university hospital, Dep. of ophthalmology
Principal Investigator: Per L Poulsen, MD, PhD Aarhus University hospital, Dep. of endocrinology (M)
  More Information

Responsible Party: Toke Bek/Professor, Aarhus University Hospital
ClinicalTrials.gov Identifier: NCT00337298     History of Changes
Other Study ID Numbers: Jmehl01
First Submitted: June 14, 2006
First Posted: June 15, 2006
Last Update Posted: June 23, 2009
Last Verified: June 2009

Keywords provided by University of Aarhus:
Blood Pressure

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Retinal Diseases
Diabetic Retinopathy
Eye Diseases
Diabetes Complications
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Cardiotonic Agents
Protective Agents
Physiological Effects of Drugs